Contineum Therapeutics, Class Stock Price Prediction
| CTNM Stock | 12.68 0.37 3.01% |
Momentum 66
Buy Stretched
Oversold | Overbought |
EPS Estimate Next Quarter (0.65) | EPS Estimate Current Year (2.05) | EPS Estimate Next Year (2.24) | Wall Street Target Price 22.0371 | EPS Estimate Current Quarter (0.46) |
Using Contineum Therapeutics, hype-based prediction, you can estimate the value of Contineum Therapeutics, Class from the perspective of Contineum Therapeutics, response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Contineum Therapeutics, using Contineum Therapeutics,'s stock options and short interest. It helps to benchmark the overall future attitude of investors towards Contineum using crowd psychology based on the activity and movement of Contineum Therapeutics,'s stock price.
Contineum Therapeutics, Implied Volatility | 2.53 |
Contineum Therapeutics,'s implied volatility exposes the market's sentiment of Contineum Therapeutics, Class stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Contineum Therapeutics,'s implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Contineum Therapeutics, stock will not fluctuate a lot when Contineum Therapeutics,'s options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Contineum Therapeutics, to buy its stock at a price that has no basis in reality. In that case, they are not buying Contineum because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Contineum Therapeutics, after-hype prediction price | USD 12.68 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Contineum contract
Based on the Rule 16, the options market is currently suggesting that Contineum Therapeutics, Class will have an average daily up or down price movement of about 0.16% per day over the life of the 2026-02-20 option contract. With Contineum Therapeutics, trading at USD 12.68, that is roughly USD 0.0201 . If you think that the market is fully incorporating Contineum Therapeutics,'s daily price movement you should consider acquiring Contineum Therapeutics, Class options at the current volatility level of 2.53%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Contineum | Build AI portfolio with Contineum Stock |
Contineum Therapeutics, After-Hype Price Prediction Density Analysis
As far as predicting the price of Contineum Therapeutics, at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Contineum Therapeutics, or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Contineum Therapeutics,, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Contineum Therapeutics, Estimiated After-Hype Price Volatility
In the context of predicting Contineum Therapeutics,'s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Contineum Therapeutics,'s historical news coverage. Contineum Therapeutics,'s after-hype downside and upside margins for the prediction period are 8.67 and 16.69, respectively. We have considered Contineum Therapeutics,'s daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Contineum Therapeutics, is somewhat reliable at this time. Analysis and calculation of next after-hype price of Contineum Therapeutics, is based on 3 months time horizon.
Contineum Therapeutics, Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Contineum Therapeutics, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Contineum Therapeutics, backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Contineum Therapeutics,, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.18 | 3.98 | 0.00 | 0.02 | 7 Events / Month | 7 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
12.68 | 12.68 | 0.00 |
|
Contineum Therapeutics, Hype Timeline
Contineum Therapeutics, is currently traded for 12.68. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.02. Contineum is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at 0.18%. %. The volatility of related hype on Contineum Therapeutics, is about 3209.68%, with the expected price after the next announcement by competition of 12.70. About 58.0% of the company shares are held by institutions such as insurance companies. The book value of Contineum Therapeutics, was currently reported as 6.18. The company recorded a loss per share of 2.25. Contineum Therapeutics, had not issued any dividends in recent years. Given the investment horizon of 90 days the next estimated press release will be in about 7 days. Check out Contineum Therapeutics, Basic Forecasting Models to cross-verify your projections.Contineum Therapeutics, Related Hype Analysis
Having access to credible news sources related to Contineum Therapeutics,'s direct competition is more important than ever and may enhance your ability to predict Contineum Therapeutics,'s future price movements. Getting to know how Contineum Therapeutics,'s peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Contineum Therapeutics, may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MREO | Mereo BioPharma Group | (0.04) | 7 per month | 3.04 | 0.09 | 9.27 | (4.91) | 20.57 | |
| KYTX | Kyverna Therapeutics, Common | 0.41 | 10 per month | 7.95 | 0.1 | 13.12 | (9.60) | 65.24 | |
| LXEO | Lexeo Therapeutics, Common | (0.13) | 8 per month | 3.26 | 0.19 | 9.33 | (6.73) | 38.59 | |
| SLN | Silence Therapeutics PLC | 0.17 | 8 per month | 3.43 | 0.06 | 10.00 | (5.16) | 22.91 | |
| ACIU | AC Immune | (0.03) | 8 per month | 5.45 | 0.07 | 10.46 | (10.64) | 39.46 | |
| ANRO | Alto Neuroscience, | 1.10 | 10 per month | 5.06 | 0.22 | 12.56 | (8.94) | 100.99 | |
| ALDX | Aldeyra | (0.25) | 9 per month | 3.91 | 0.02 | 7.89 | (5.93) | 41.93 | |
| CAPR | Capricor Therapeutics | 0.15 | 8 per month | 4.38 | 0.13 | 11.97 | (7.92) | 386.29 | |
| CADL | Candel Therapeutics | (0.11) | 10 per month | 4.08 | 0.05 | 8.63 | (6.30) | 22.71 | |
| AMRN | Amarin PLC | (0.03) | 8 per month | 0.00 | (0.06) | 4.18 | (4.40) | 23.79 |
Contineum Therapeutics, Additional Predictive Modules
Most predictive techniques to examine Contineum price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Contineum using various technical indicators. When you analyze Contineum charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Contineum Therapeutics, Predictive Indicators
The successful prediction of Contineum Therapeutics, stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Contineum Therapeutics, Class, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Contineum Therapeutics, based on analysis of Contineum Therapeutics, hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Contineum Therapeutics,'s market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Contineum Therapeutics,'s related companies. | 2024 | 2025 (projected) | Interest Debt Per Share | 0.32 | 0.31 | Revenue Per Share | 1.78 | 1.58 |
Story Coverage note for Contineum Therapeutics,
The number of cover stories for Contineum Therapeutics, depends on current market conditions and Contineum Therapeutics,'s risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Contineum Therapeutics, is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Contineum Therapeutics,'s long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Contineum Therapeutics, Short Properties
Contineum Therapeutics,'s future price predictability will typically decrease when Contineum Therapeutics,'s long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Contineum Therapeutics, Class often depends not only on the future outlook of the potential Contineum Therapeutics,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Contineum Therapeutics,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.4 M | |
| Cash And Short Term Investments | 204.8 M |
Check out Contineum Therapeutics, Basic Forecasting Models to cross-verify your projections. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Contineum Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.